Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
News|Articles|November 1, 2004
- Pharmaceutical Technology-11-01-2004
- Volume 2004 Supplement
- Issue 8
Challenging "The Process is the Product": Clarifying the Role of Information Technology in Biopharmaceutical Process Development
The author argues that information technology solutions will play a major part in confirming-by experimental and statistical validation-that bioprocesses may be interchangeable and therefore generic. The bioprocessing ANDA will define both in-house and contract manufacturing.
Advertisement
Articles in this issue
almost 22 years ago
Named Anchor Problemabout 22 years ago
Why Search Matters: Information Retrieval in the Pharmaceutical IndustryAdvertisement
Related to this article
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Panelists on the PharmTech AI Pulse Check weigh a December AI playbook, EMA/MHRA moves, PCCP accountability gaps, and MCP-ready regulatory guidance.
France’s 2030 Health Initiative is driving growth in biotechnology, health innovation, biomanufacturing, and digital health.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the First Factor XIa Approval Means for Developers
2
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
France Remains One of Europe’s Leading Biotech Funding Hubs
5